Mainz Biomed NV
MYNZ
Company Profile
Business description
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company’s flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
Contact
Robert Koch Strasse 50
Sirius Gutenberg Park
MainzRP55129
DEUT: +49 61315542860
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
26
Stocks News & Analysis
stocks
Nvidia: Collaboration with Intel might bring some goodwill with the US
We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.
stocks
What now for Santos after takeover offer collapses?
Our Fair Value estimate once again reflects the stand-alone business and its growth potential.
stocks
Morningstar initiates coverage on small cap ASX REIT
Coverage of ASX listed REIT as investor interest in property continues to grow.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,061.20 | 20.50 | -0.23% |
| CAC 40 | 7,853.59 | 1.02 | -0.01% |
| DAX 40 | 23,639.41 | 35.12 | -0.15% |
| Dow JONES (US) | 46,321.73 | 179.31 | 0.39% |
| FTSE 100 | 9,216.67 | 11.44 | -0.12% |
| HKSE | 26,545.10 | 0.25 | 0.00% |
| NASDAQ | 22,591.27 | 120.55 | 0.54% |
| Nikkei 225 | 45,045.81 | 257.62 | -0.57% |
| NZX 50 Index | 13,231.66 | 111.63 | 0.85% |
| S&P 500 | 6,660.72 | 28.76 | 0.43% |
| S&P/ASX 200 | 8,773.50 | 18.70 | -0.21% |
| SSE Composite Index | 3,820.09 | 11.57 | -0.30% |